Medicus Pharma (NASDAQ: MDCX) is making significant strides in the fight against skin cancer by introducing a non-invasive, targeted chemotherapy solution designed to deliver treatment directly to tumor sites. This breakthrough approach offers a less painful and more effective alternative to conventional surgeries, which often involve lengthy recovery times and potential complications. With the global skin cancer treatment market projected to surpass $20 billion by 2030, Medicus Pharma is well-positioned to address the rising demand for safe, cost-effective therapies.

‍